Aligos Therapeutics, Inc.

Informe acción NasdaqCM:ALGS

Capitalización de mercado: US$63.2m

Salud financiera de hoja de balance de Aligos Therapeutics

Salud financiera controles de criterios 6/6

Aligos Therapeutics tiene unos fondos propios totales de $54.8M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $85.9M y $31.0M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$135.70m
PatrimonioUS$92.08m
Total pasivoUS$59.45m
Activos totalesUS$151.53m

Actualizaciones recientes sobre salud financiera

Recent updates

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24
Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study

Oct 30

Análisis de la situación financiera

Pasivos a corto plazo: ALGSLos activos a corto plazo ($74.6M) de la empresa superan a sus pasivos a corto plazo ($22.5M).

Pasivo a largo plazo: ALGSLos activos a corto plazo ($74.6M) superan a sus pasivos a largo plazo ($8.6M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ALGS está libre de deudas.

Reducción de la deuda: ALGS no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALGS tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ALGS dispone de suficiente liquidez para 1.7 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 12.3% cada año.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target